source
- Regeneron wins FDA approval for Pasatru, targeting rare bone disease FOPThe U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' drug Pasatru for the treatment of fibrodysplasia ossificans progressiva (FOP), a very rare condition in which muscle an…
- Moderna-Merck mRNA cancer vaccine shows landmark interim success in melanoma trialAn interim analysis of a Phase 3 trial of an individualized mRNA cancer vaccine from Moderna and Merck showed the treatment met its primary goals. The vaccine, given together with Merck's immunothe…